MA39849A - Souches de listeria utilisées comme vaccin recombinant et procédé de production - Google Patents

Souches de listeria utilisées comme vaccin recombinant et procédé de production

Info

Publication number
MA39849A
MA39849A MA039849A MA39849A MA39849A MA 39849 A MA39849 A MA 39849A MA 039849 A MA039849 A MA 039849A MA 39849 A MA39849 A MA 39849A MA 39849 A MA39849 A MA 39849A
Authority
MA
Morocco
Prior art keywords
recombinant
recombinant listeria
producing
methods
same
Prior art date
Application number
MA039849A
Other languages
English (en)
Inventor
Robert Petit
Anu Wallecha
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MA39849A publication Critical patent/MA39849A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés de traitement, de protection contre une tumeur ou un cancer et d'induction d'une réponse immunitaire contre cette tumeur ou ce cancer, comprenant l'étape d'administration à un patient d'une souche de listeria recombinante comportant un acide nucléique codant pour une protéine prfa mutante qui assure la restauration partielle de la fonction prfa.
MA039849A 2014-04-24 2015-04-14 Souches de listeria utilisées comme vaccin recombinant et procédé de production MA39849A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983732P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
MA39849A true MA39849A (fr) 2017-03-01

Family

ID=54333010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039849A MA39849A (fr) 2014-04-24 2015-04-14 Souches de listeria utilisées comme vaccin recombinant et procédé de production

Country Status (15)

Country Link
US (2) US10258679B2 (fr)
EP (1) EP3134510B1 (fr)
JP (3) JP7009061B2 (fr)
KR (2) KR102491332B1 (fr)
CN (1) CN106459887A (fr)
AU (1) AU2015250111A1 (fr)
BR (1) BR112016024352A2 (fr)
CA (1) CA2946716A1 (fr)
IL (1) IL248483A0 (fr)
MA (1) MA39849A (fr)
MX (1) MX2016013985A (fr)
RU (1) RU2016145464A (fr)
SG (2) SG11201608820WA (fr)
TW (2) TWI722858B (fr)
WO (1) WO2015164121A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2012125551A1 (fr) 2011-03-11 2012-09-20 Advaxis Adjuvants à base de listeria
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (fr) 2014-02-18 2017-10-11 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
SG11201702857PA (en) * 2014-10-14 2017-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
CN106978381A (zh) * 2017-03-23 2017-07-25 上海理工大学 prfA基因缺失单核细胞增生李斯特氏菌及制备方法
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
CA3080835A1 (fr) 2017-10-31 2019-05-09 Pantarhei Bioscience B.V. Methodes immunotherapeutiques pour traiter et/ou prevenir le cancer du poumon
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3762719A1 (fr) * 2018-03-09 2021-01-13 Advaxis, Inc. Compositions et méthodes d'évaluation d'atténuation et d'infectivité de souches de listeria
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021259963A1 (fr) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunisation contre wnt4 pour le traitement et la prophylaxie du cancer du sein
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN118900696A (zh) 2021-10-19 2024-11-05 科学医疗有限责任公司 雄性避孕
CN116218754B (zh) * 2023-04-10 2025-06-03 四川大学 一种提高绵羊李斯特菌膜囊泡产量的方法及应用
CN119060155B (zh) * 2024-11-07 2025-03-07 山东大学 一种蛋白在调节肠道稳态及抵抗致病菌感染中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7635479B2 (en) 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
CA2486980A1 (fr) 2002-05-29 2003-12-11 The Regents Of The University Of California Listeria spp. attenuee et leurs methodes d'utilisation
CA2512812A1 (fr) 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methodes et trousses renforcant l'immunogenecite d'un vecteur de vaccin bacterien
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
PT2942391T (pt) * 2004-08-13 2018-10-09 Univ Pennsylvania Métodos de produção de vacinas não resistentes aos antibióticos
US7855064B2 (en) 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
CA2584130A1 (fr) * 2004-10-18 2006-04-27 Medimmune, Inc. Procede de croissance de listeria a hautes densites cellulaires
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US8241636B2 (en) 2006-08-15 2012-08-14 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2147092A4 (fr) 2007-04-16 2010-06-09 Univ Pennsylvania Souche de listeria exempte de résistance aux antibiotiques et procédé pour la construction et l'utilisation de celle-ci
WO2009143167A2 (fr) 2008-05-19 2009-11-26 Advaxis Système de double distribution pour des antigènes hétérologues
US20140234370A1 (en) 2009-11-11 2014-08-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
CA2724649A1 (fr) * 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comportant un mutant prfa de listeria, et leurs procedes d'utilisation
KR20110045010A (ko) * 2008-07-24 2011-05-03 아두로 바이오테크 Ｃ형 간염의 치료를 위한 조성물 및 방법
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011060260A2 (fr) 2009-11-11 2011-05-19 Advaxis Compositions et méthodes de prévention de mutation d'échappement dans le traitement des tumeurs surexprimant her2/neu
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
US20110305724A1 (en) 2010-04-19 2011-12-15 Yvonne Paterson Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
SI2640842T1 (sl) 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
WO2012125551A1 (fr) 2011-03-11 2012-09-20 Advaxis Adjuvants à base de listeria
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (fr) 2014-02-18 2017-10-11 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
RU2016137834A (ru) 2014-02-25 2018-03-29 Адваксис, Инк. КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
MA39717A (fr) 2014-03-05 2017-01-11 Advaxis Inc Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
JP2017514904A (ja) 2014-05-02 2017-06-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２陽性ガンの治療のための免疫療法および放射線療法の併用
KR20170052569A (ko) 2014-07-18 2017-05-12 어드박시스, 인크. 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
WO2016011320A1 (fr) 2014-07-18 2016-01-21 Advaxis, Inc. Système de largage d'antigènes hétérologues bivalent dérivé de listéria
SG11201700092XA (en) 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
JP2017522322A (ja) 2014-07-18 2017-08-10 アドバクシス， インコーポレイテッド 抗腫瘍応答を引き出すためのリステリアベースの免疫原性組成物
SG11201702857PA (en) 2014-10-14 2017-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41217A (fr) 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
WO2016126876A2 (fr) 2015-02-03 2016-08-11 Advaxis, Inc. Adjuvants à base de listeria
WO2016126878A2 (fr) 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Immunomodulation reposant sur listeria
US20160220652A1 (en) 2015-02-03 2016-08-04 Advaxis, Inc. Methods of using recombinant listeria vaccine strains in disease immunotherapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016154412A2 (fr) 2015-03-26 2016-09-29 The Trustees Of The University Of Pennsylvania Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement d'un cancer du pancréas
US20180104284A1 (en) 2015-05-13 2018-04-19 Advaxis, Inc. Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof
CN107847611A (zh) 2015-05-26 2018-03-27 阿德瓦希斯公司 个性化的基于递送载体的免疫疗法及其用途
EP3313975A4 (fr) 2015-06-24 2019-03-13 Advaxis, Inc. Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
TW201723171A (zh) 2015-09-15 2017-07-01 艾法西斯公司 基於李斯特菌屬之免疫原性組成物及其於癌症預防與治療中之使用方法
US20180265879A1 (en) 2015-09-15 2018-09-20 Advaxis, Inc. Manufacturing method of an immunotherapeutic formulation comprising a recombinant listeria strain
AU2016324170A1 (en) 2015-09-17 2018-04-12 Advaxis, Inc. Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
AU2016340148A1 (en) 2015-10-14 2018-05-31 Advaxis, Inc. Recombinant Listeria strains and methods of using the same in cancer immunotherapy
WO2017085691A1 (fr) 2015-11-20 2017-05-26 Advaxis, Inc. Procédé et dispositif de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria recombinante
JP2018537511A (ja) 2015-12-16 2018-12-20 アドバクシス， インコーポレイテッド リステリア系免疫療法およびその使用方法
WO2017132547A1 (fr) 2016-01-27 2017-08-03 Advaxis, Inc. Immunothérapie à base de vecteurs d'administration personnalisés et utilisations associées
EP3481854A4 (fr) 2016-07-05 2020-07-29 Advaxis, Inc. Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms et procédés d'utilisation correspondants
EP3534944A4 (fr) 2016-11-07 2020-07-01 Advaxis, Inc. Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
WO2018129306A1 (fr) 2017-01-05 2018-07-12 Advaxis, Inc. Souches vaccinales de listeria recombinées et leurs méthodes d'utilisation en immunothérapie anticancéreuse

Also Published As

Publication number Publication date
TW201546276A (zh) 2015-12-16
TWI722858B (zh) 2021-03-21
WO2015164121A1 (fr) 2015-10-29
KR20160145627A (ko) 2016-12-20
SG11201608820WA (en) 2016-11-29
JP7009061B2 (ja) 2022-01-25
AU2015250111A1 (en) 2016-12-08
CN106459887A (zh) 2017-02-22
KR20220021021A (ko) 2022-02-21
EP3134510B1 (fr) 2023-11-01
JP7300041B2 (ja) 2023-06-28
RU2016145464A (ru) 2018-05-24
JP2022105768A (ja) 2022-07-14
US10258679B2 (en) 2019-04-16
JP2017513502A (ja) 2017-06-01
US20190240303A1 (en) 2019-08-08
TWI692525B (zh) 2020-05-01
IL248483A0 (en) 2016-12-29
JP2020099352A (ja) 2020-07-02
KR102359691B1 (ko) 2022-02-10
CA2946716A1 (fr) 2015-10-29
EP3134510A1 (fr) 2017-03-01
TW202041671A (zh) 2020-11-16
US20170042996A1 (en) 2017-02-16
KR102491332B1 (ko) 2023-01-27
EP3134510A4 (fr) 2018-04-25
BR112016024352A2 (pt) 2018-01-23
MX2016013985A (es) 2017-01-11
SG10202011841WA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2016013985A (es) Cepas de vacunas de listeria recombinante y metodos para producir las mismas.
MX2017004729A (es) Terapia de combinacion para usar en la terapia contra el cancer.
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
NZ745327A (en) Whole-cell cancer vaccines and methods for selection thereof
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
WO2015134722A3 (fr) Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
MX2017004007A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX379450B (es) Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
HK1258860A1 (zh) 含有重组李斯特氏菌株的免疫治疗制剂的制作方法
NZ742663A (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
EA033538B1 (ru) Композиции и способы усиления иммунного ответа на кишечные патогены
MX382952B (es) Métodos de producción de proteínas de cadena doble en bacterias.
WO2020023845A3 (fr) Procédés d'identification d'épitopes dérivés d'édition d'arn qui provoquent des réponses immunitaires dans le cancer
MY191217A (en) Group a streptococcus vaccine
MX365560B (es) Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes.
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
PH12018501532A1 (en) Cancer vaccines